ACADIA Pharmaceuticals Inc. (ACAD-NASDAQ)
Interview with: Uli Hacksell, Ph.D., CEO
Business News, Financial News, Stocks, Money & Investment Ideas, CEO Interview
and Information on their drug discovery and clinical development of novel treatments for central nervous system disorders with five drug programs in clinical and preclinical development that include Parkinson's disease, schizophrenia, neuropathic pain and glaucoma.

Cover Story

CEOCFO Interview Index

CEOCFO Current Issue

Cover Story Archives

Future Features

Analyst Interviews

Corporate Financials

Archived Interviews
 
About CEOCFOinterviews.com

Contact & Ordering

This is a printer friendly page!

ACADIA Pharmaceutical has assembled a strong management team with extensive experience from big pharma operations and outstanding scientific expertise to ensure successful drug discovery and development efforts



Healthcare
Biotechnology
(ACAD-NASDAQ)

ACADIA Pharmaceuticals Inc.




Uli Hacksell, Ph.D.
Chief Executive Officer

Interview conducted by:
Lynn Fosse, Senior Editor
CEOCFOinterviews.com
January 13, 2005

To order the complete January 13, 2005 Issue of CEOCFOinterviews.com left click below for our secure forms:

Purchase NOW!

There is a $5.00 charge for each current issue!

disclaimers

Any reproduction or further distribution of this article without the express written consent of CEOCFOinterviews.com is prohibited.

Newsflash!

To view Releases highlight & left click on the company name!